Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

Core Viewpoint - Zoetis Inc. announces the retirement of Dr. Rob Polzer at the end of 2025 and the appointment of Dr. Kevin Esch as the new President of Research & Development starting January 1, 2026, highlighting a planned succession to maintain momentum in innovation within the animal health sector [1][2][3]. Leadership Transition - Dr. Rob Polzer will retire on February 28, 2026, after a decade of contributions to veterinary medicine and innovation, and will serve as a scientific advisor through 2026 to ensure a smooth transition [1][3]. - Dr. Kevin Esch, currently Senior Vice President of Global Therapeutics, will take over the role, bringing over 10 years of experience as a veterinarian and a strong background in research and development [2][7]. Innovation and Growth Strategy - Zoetis is committed to advancing animal care globally through a robust innovation pipeline, with expectations for significant product approvals in major markets annually for the next several years [4]. - The company has introduced 17 blockbuster products and over 2,000 new products and lifecycle innovations in the past 12 years, investing more in R&D than any other animal health company [4]. Upcoming Events - An Innovation Webcast is scheduled for December 2, 2025, to update investors and the public on Zoetis' innovative pipeline and strategic approach to addressing unmet needs in the industry [5]. Contributions of Dr. Rob Polzer - Under Dr. Polzer's leadership, Zoetis has launched several groundbreaking products and established new markets, significantly transforming standards of care in animal health [10][11]. - His tenure has been marked by a focus on scientific rigor and collaboration, leading to advancements in therapies, vaccines, and digital solutions [10][11]. Background of Dr. Kevin Esch - Dr. Esch has held various influential roles within Zoetis since joining in 2014, overseeing global research and development efforts and managing key acquisitions [7][8]. - His educational background includes a Doctor of Veterinary Medicine, a Master of Public Health, and a Ph.D. in Immunobiology, reflecting a strong commitment to veterinary medicine [8][9].